Evaluating MGUS with Free Light Chain Assays in Clinical Practice

Advancing Healthcare Webinar Series

Free light chains, kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple Myeloma is called Monoclonal Gammopathy of Undetermined Significance (MGUS) and although these individuals are not immediately treated, they are closely monitored due to their risk of progression to Multiple Myeloma¹.

Dr. John Mitsios, Ph.D. discusses the potential clinical usage of the N-Latex FLC assay in evaluation of MGUS. In this presentation he:

• Defines multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS)
• Describes the clinical criteria used to define multiple myeloma
• Describes the use of free light chains in the evaluation of MGUS

Speaker:

Dr. Mitsios graduated from the University of Ioannina, Greece with a PhD in Chemistry. Upon completion of his doctoral thesis, he then went on to complete a post-doctoral fellowship at the University of California, San Diego. Dr. Mitsios then transitioned to the world of Clinical Chemistry and completed a fellowship at Washington University in St. Louis, MO. His primary research interest throughout his education and training has been in coagulation, with an emphasis on platelet function and biology. Dr. Mitsios joined Siemens-Healthineers as a clinical consultant as part of the Scientific and Clinical Affairs team. In addition, Dr. Mitsios has co-authored 20 peer-reviewed articles and 3 book chapters.